A 2025 systematic review and meta-analysis published in Obesity Reviews analyzed eight randomized controlled trials that included participants with a BMI of 27 or higher (N=2,372) who had been on GLP-1 receptor agonist therapy and then stopped
Some are navigating cost or insurance changes, while others are dealing with side effects
For GLP-1 agonists, step therapy is much less commonly used as a utilization management tool, with fewer than 1 in 4 Marketplace plans requiring step therapy for each of the drugs included in this analysis
11 Impact on PharmD/CDCES: Pharmacists/CDCES can help identify patients that would most benefit from tirzepatides A1c lowering and weight reducing effects Pharmacists/CDCES can provide appropriate patient counseling regarding tirzepatides administration, benefits, adverse drug reactions, and storage Pharmacists/CDCES can assist other healthcare providers to safely transition patients from a GLP-1 RA to tirzepatide Pharmacists can facilitate insurance/cost barriers for eligible patients based on approved indications References: Type 2 diabetes treatment to lower A1C: Mounjaro(tirzepatide).Mounjaro
:
By reducing NNMT activity, the bodys ability to break down fat and generate cellular energy is restored